Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tocilizumab plus standard treatment versus placebo plus standard treatment for hospitalized COVID-19
IRCT20201024049134N2Phase 3Completed
- Sponsor
- Babol University of Medical Sciences
- Start
- Jun 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of tocilizumab in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Babol University of Medical Sciences. Primary endpoint: Time to mechanical ventilation, intubation, or death. Started Jun 2021; status: completed.
02
Drugs
tocilizumab
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on IRCT20201024049134N2.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20201024049134N2.